A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

June 17, 2022 updated by: Idorsia Pharmaceuticals Ltd.

A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
70

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Groningen, Netherlands, 9713 GZ
        • QPS Netherlands B.V.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

General Inclusion Criteria:

  • Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
  • Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years (inclusive) at Screening.
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.
  • Male subjects with a partner who might become pregnant must either be vasectomized or agree to practice adequate contraception from admission to the study site until 3 months after dosing, or the partner must consistently and correctly use a highly effective method of contraception.

Inclusion Criteria for Part B:

  • Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use a highly effective method of contraception with a failure rate of less than 1% per year, be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

General Exclusion Criteria:

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment.

Exclusion Criteria for the absorption,distribution, metabolism and excretion (ADME) evaluation:

  • Radiation exposure, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 milli sievert (mSv) in the last 12 months or 10 mSv in the last 5 years. Occupationally exposed workers, as defined in the relevant Ionising Radiation Regulations, must not participate in the study.
  • Participation in any study involving administration of any Carbon-14 (14C) radiolabeled compound within the 12 months prior to Screening.

Exclusion Criteria for Part B:

  • Pregnant or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Part A (single ascending dose) Dose A1
Single dose A1 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A2
Single dose A2 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A3
Single dose A3 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A4
Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A5
Single dose A5 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A6
Single dose A6 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A7
Single dose A7 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part A (single ascending dose arm) Dose A8
Single dose A8 of ACT-777991.
Drug: ACT-777991 (SAD)
ACT-777991 administered as hard capsules for oral use.
Drug: Placebo (SAD)
ACT-777991 matching placebo administered as hard capsules for oral use.
Experimental: Part B (multiple ascending dose) Dose B1
Multiple doses B1 of ACT-777991.
Drug: ACT-777991 (MAD)
ACT-777991 administered as hard capsules for oral use, once daily.
Drug: Placebo (MAD)
Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B2
Multiple doses B2 of ACT-777991.
Drug: ACT-777991 (MAD)
ACT-777991 administered as hard capsules for oral use, once daily.
Drug: Placebo (MAD)
Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B3
Multiple doses B3 of ACT-777991.
Drug: ACT-777991 (MAD)
ACT-777991 administered as hard capsules for oral use, once daily.
Drug: Placebo (MAD)
Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B4
Multiple doses B4 of ACT-777991.
Drug: ACT-777991 (MAD)
ACT-777991 administered as hard capsules for oral use, once daily.
Drug: Placebo (MAD)
Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part B (multiple ascending dose) Dose B5
Multiple doses B5 of ACT-777991.
Drug: ACT-777991 (MAD)
ACT-777991 administered as hard capsules for oral use, once daily.
Drug: Placebo (MAD)
Matching placebo administered as hard capsules for oral use, once daily.
Experimental: Part A (single ascending dose) Absolute Bioavailability
Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.
Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)
Single dose of 14C-ACT-777991 microtracer, administered intravenously.
Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)
Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
Experimental: Part B (multiple ascending dose) ADME
Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.
Drug: 14C-ACT-777991 microtracer (MAD - ADME)
Single dose of 14C-ACT-777991 microtracer, oral solution..
Drug: Microtracer matching placebo (MAD - ADME)
Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Incidence of treatment-emergent adverse events.
Time Frame: From first dose on Day 1 to Day 4 after the last dose was administered
From first dose on Day 1 to Day 4 after the last dose was administered

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Maximum plasma concentration (Cmax) of ACT-777991
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Time to reach Cmax (tmax) of ACT-777991
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
All cohorts: Terminal half-life (t1/2) of ACT-777991
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Part A (SAD): Absolute bioavailability of ACT-777991
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Part B (MAD): Excretion of radioactivity in urine and feces
Time Frame: Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)
Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)
Part B (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose of ACT-777991.
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Blood samples will be collected at predefined time points from Day 1 to Day 4.
Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Blood samples will be collected at predefined time points from Day 1 to Day 4.
Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Blood samples will be collected at predefined time points from Day 1 to Day 4.
Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions
Time Frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Blood samples will be collected at predefined time points from Day 1 to Day 4.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Idorsia Pharmaceuticals Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 29, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 26, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 21, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 3, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 11, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 15, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 21, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 17, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ID-089-101
  • 2020-004464-26 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on ACT-777991 (SAD)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings